[18F]FMCH PET/CT biomarkers and similarity analysis to refine the definition of oligometastatic prostate cancer

Abstract Background The role of image-derived biomarkers in recurrent oligometastatic Prostate Cancer (PCa) is unexplored. This paper aimed to evaluate [18F]FMCH PET/CT radiomic analysis in patients with recurrent PCa after primary radical therapy. Specifically, we tested intra-patient lesions simil...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Martina Sollini, Francesco Bartoli, Lara Cavinato, Francesca Ieva, Alessandra Ragni, Andrea Marciano, Roberta Zanca, Luca Galli, Fabiola Paiar, Francesco Pasqualetti, Paola Anna Erba
Formato:	article
Lenguaje:	EN
Publicado:	SpringerOpen 2021
Materias:	[18F]FMCH PET/CT Epithelial-mesenchymal transition Number of lesions Oligometastatic PCa Radiomics Silhouette index Medical physics. Medical radiology. Nuclear medicine R895-920
Acceso en línea:	https://doaj.org/article/d6682af7111245f29b5fa1452c9b2e31
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d6682af7111245f29b5fa1452c9b2e31
record_format	dspace
spelling	oai:doaj.org-article:d6682af7111245f29b5fa1452c9b2e312021-11-28T12:15:08Z[18F]FMCH PET/CT biomarkers and similarity analysis to refine the definition of oligometastatic prostate cancer10.1186/s13550-021-00858-82191-219Xhttps://doaj.org/article/d6682af7111245f29b5fa1452c9b2e312021-11-01T00:00:00Zhttps://doi.org/10.1186/s13550-021-00858-8https://doaj.org/toc/2191-219XAbstract Background The role of image-derived biomarkers in recurrent oligometastatic Prostate Cancer (PCa) is unexplored. This paper aimed to evaluate [18F]FMCH PET/CT radiomic analysis in patients with recurrent PCa after primary radical therapy. Specifically, we tested intra-patient lesions similarity in oligometastatic and plurimetastatic PCa, comparing the two most used definitions of oligometastatic disease. Methods PCa patients eligible for [18F]FMCH PET/CT presenting biochemical failure after first-line curative treatments were invited to participate in this prospective observational trial. PET/CT images of 92 patients were visually and quantitatively analyzed. Each patient was classified as oligometastatic or plurimetastatic according to the total number of detected lesions (up to 3 and up to 5 or > 3 and > 5, respectively). Univariate and intra-patient lesions' similarity analysis were performed. Results [18F]FMCH PET/CT identified 370 lesions, anatomically classified as regional lymph nodes and distant metastases. Thirty-eight and 54 patients were designed oligometastatic and plurimetastatic, respectively, using a 3-lesion threshold. The number of oligometastic scaled up to 60 patients (thus 32 plurimetastatic patients) with a 5-lesion threshold. Similarity analysis showed high lesions' heterogeneity. Grouping patients according to the number of metastases, patients with oligometastatic PCa defined with a 5-lesion threshold presented lesions heterogeneity comparable to plurimetastic patients. Lesions within patients having a limited tumor burden as defined by three lesions were characterized by less heterogeneity. Conclusions We found a comparable heterogeneity between patients with up to five lesions and plurimetastic patients, while patients with up to three lesions were less heterogeneous than plurimetastatic patients, featuring different cells phenotypes in the two groups. Our results supported the use of a 3-lesion threshold to define oligometastatic PCa.Martina SolliniFrancesco BartoliLara CavinatoFrancesca IevaAlessandra RagniAndrea MarcianoRoberta ZancaLuca GalliFabiola PaiarFrancesco PasqualettiPaola Anna ErbaSpringerOpenarticle[18F]FMCH PET/CTEpithelial-mesenchymal transitionNumber of lesionsOligometastatic PCaRadiomicsSilhouette indexMedical physics. Medical radiology. Nuclear medicineR895-920ENEJNMMI Research, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	[18F]FMCH PET/CT Epithelial-mesenchymal transition Number of lesions Oligometastatic PCa Radiomics Silhouette index Medical physics. Medical radiology. Nuclear medicine R895-920
spellingShingle	[18F]FMCH PET/CT Epithelial-mesenchymal transition Number of lesions Oligometastatic PCa Radiomics Silhouette index Medical physics. Medical radiology. Nuclear medicine R895-920 Martina Sollini Francesco Bartoli Lara Cavinato Francesca Ieva Alessandra Ragni Andrea Marciano Roberta Zanca Luca Galli Fabiola Paiar Francesco Pasqualetti Paola Anna Erba [18F]FMCH PET/CT biomarkers and similarity analysis to refine the definition of oligometastatic prostate cancer
description	Abstract Background The role of image-derived biomarkers in recurrent oligometastatic Prostate Cancer (PCa) is unexplored. This paper aimed to evaluate [18F]FMCH PET/CT radiomic analysis in patients with recurrent PCa after primary radical therapy. Specifically, we tested intra-patient lesions similarity in oligometastatic and plurimetastatic PCa, comparing the two most used definitions of oligometastatic disease. Methods PCa patients eligible for [18F]FMCH PET/CT presenting biochemical failure after first-line curative treatments were invited to participate in this prospective observational trial. PET/CT images of 92 patients were visually and quantitatively analyzed. Each patient was classified as oligometastatic or plurimetastatic according to the total number of detected lesions (up to 3 and up to 5 or > 3 and > 5, respectively). Univariate and intra-patient lesions' similarity analysis were performed. Results [18F]FMCH PET/CT identified 370 lesions, anatomically classified as regional lymph nodes and distant metastases. Thirty-eight and 54 patients were designed oligometastatic and plurimetastatic, respectively, using a 3-lesion threshold. The number of oligometastic scaled up to 60 patients (thus 32 plurimetastatic patients) with a 5-lesion threshold. Similarity analysis showed high lesions' heterogeneity. Grouping patients according to the number of metastases, patients with oligometastatic PCa defined with a 5-lesion threshold presented lesions heterogeneity comparable to plurimetastic patients. Lesions within patients having a limited tumor burden as defined by three lesions were characterized by less heterogeneity. Conclusions We found a comparable heterogeneity between patients with up to five lesions and plurimetastic patients, while patients with up to three lesions were less heterogeneous than plurimetastatic patients, featuring different cells phenotypes in the two groups. Our results supported the use of a 3-lesion threshold to define oligometastatic PCa.
format	article
author	Martina Sollini Francesco Bartoli Lara Cavinato Francesca Ieva Alessandra Ragni Andrea Marciano Roberta Zanca Luca Galli Fabiola Paiar Francesco Pasqualetti Paola Anna Erba
author_facet	Martina Sollini Francesco Bartoli Lara Cavinato Francesca Ieva Alessandra Ragni Andrea Marciano Roberta Zanca Luca Galli Fabiola Paiar Francesco Pasqualetti Paola Anna Erba
author_sort	Martina Sollini
title	[18F]FMCH PET/CT biomarkers and similarity analysis to refine the definition of oligometastatic prostate cancer
title_short	[18F]FMCH PET/CT biomarkers and similarity analysis to refine the definition of oligometastatic prostate cancer
title_full	[18F]FMCH PET/CT biomarkers and similarity analysis to refine the definition of oligometastatic prostate cancer
title_fullStr	[18F]FMCH PET/CT biomarkers and similarity analysis to refine the definition of oligometastatic prostate cancer
title_full_unstemmed	[18F]FMCH PET/CT biomarkers and similarity analysis to refine the definition of oligometastatic prostate cancer
title_sort	[18f]fmch pet/ct biomarkers and similarity analysis to refine the definition of oligometastatic prostate cancer
publisher	SpringerOpen
publishDate	2021
url	https://doaj.org/article/d6682af7111245f29b5fa1452c9b2e31
work_keys_str_mv	AT martinasollini 18ffmchpetctbiomarkersandsimilarityanalysistorefinethedefinitionofoligometastaticprostatecancer AT francescobartoli 18ffmchpetctbiomarkersandsimilarityanalysistorefinethedefinitionofoligometastaticprostatecancer AT laracavinato 18ffmchpetctbiomarkersandsimilarityanalysistorefinethedefinitionofoligometastaticprostatecancer AT francescaieva 18ffmchpetctbiomarkersandsimilarityanalysistorefinethedefinitionofoligometastaticprostatecancer AT alessandraragni 18ffmchpetctbiomarkersandsimilarityanalysistorefinethedefinitionofoligometastaticprostatecancer AT andreamarciano 18ffmchpetctbiomarkersandsimilarityanalysistorefinethedefinitionofoligometastaticprostatecancer AT robertazanca 18ffmchpetctbiomarkersandsimilarityanalysistorefinethedefinitionofoligometastaticprostatecancer AT lucagalli 18ffmchpetctbiomarkersandsimilarityanalysistorefinethedefinitionofoligometastaticprostatecancer AT fabiolapaiar 18ffmchpetctbiomarkersandsimilarityanalysistorefinethedefinitionofoligometastaticprostatecancer AT francescopasqualetti 18ffmchpetctbiomarkersandsimilarityanalysistorefinethedefinitionofoligometastaticprostatecancer AT paolaannaerba 18ffmchpetctbiomarkersandsimilarityanalysistorefinethedefinitionofoligometastaticprostatecancer
_version_	1718408105799188480

[18F]FMCH PET/CT biomarkers and similarity analysis to refine the definition of oligometastatic prostate cancer

Ejemplares similares